SG10201806965XA - 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer - Google Patents
3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancerInfo
- Publication number
- SG10201806965XA SG10201806965XA SG10201806965XA SG10201806965XA SG10201806965XA SG 10201806965X A SG10201806965X A SG 10201806965XA SG 10201806965X A SG10201806965X A SG 10201806965XA SG 10201806965X A SG10201806965X A SG 10201806965XA SG 10201806965X A SG10201806965X A SG 10201806965XA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- inhibitors
- aryl
- treatment
- stem cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER The invention provides compounds of Formula I as inhibitors of cancer stem cells as well as cancer stem cell pathway kinase and other related kinases, pharmaceutical compositions and uses thereof in the treatment of cancer or a related disorder in a mammal, wherein i.a. R 2 is an optionally substituted heterocycle or optionally substituted aryl; and one of R 4, R 5, R 6 and R 7 is a substituted heterocycle or substituted aryl. Y Z A X W U V T R4 R7 R1 R3 R2 R5 R6 (I)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361780248P | 2013-03-13 | 2013-03-13 | |
US201361780263P | 2013-03-13 | 2013-03-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201806965XA true SG10201806965XA (en) | 2018-09-27 |
Family
ID=50639949
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201806965XA SG10201806965XA (en) | 2013-03-13 | 2014-03-13 | 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer |
SG11201507346PA SG11201507346PA (en) | 2013-03-13 | 2014-03-13 | 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201507346PA SG11201507346PA (en) | 2013-03-13 | 2014-03-13 | 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer |
Country Status (14)
Country | Link |
---|---|
US (2) | US20160031888A1 (en) |
EP (1) | EP2970206A1 (en) |
JP (2) | JP6378308B2 (en) |
KR (1) | KR20150127249A (en) |
CN (1) | CN105408320B (en) |
AU (2) | AU2014243869A1 (en) |
BR (1) | BR112015022431A2 (en) |
CA (1) | CA2904152A1 (en) |
HK (1) | HK1220184A1 (en) |
IL (1) | IL240960A0 (en) |
MX (1) | MX2015011456A (en) |
RU (2) | RU2019104092A (en) |
SG (2) | SG10201806965XA (en) |
WO (1) | WO2014160401A1 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104876928B (en) * | 2015-05-07 | 2016-09-14 | 浙江司太立制药股份有限公司 | 7-azaindole quinoline-2-ketone compounds and preparation method thereof |
US10377749B2 (en) | 2015-08-10 | 2019-08-13 | Sumitomo Dainippon Pharma Co., Ltd. | Purification method for 5-(thiazol-4-yl)indolin-2-one derivative |
KR102109869B1 (en) * | 2015-11-12 | 2020-05-13 | 영남대학교 산학협력단 | Pharmaceutical composition comprising 7-azaindolin-2-one derivative or a pharmaceutically acceptable salt |
CN105461705B (en) * | 2015-11-30 | 2018-04-10 | 中国医科大学 | Dibenzazepine Zhuo diketone anti-tumor compounds and preparation method thereof |
CA3029596A1 (en) | 2016-06-28 | 2018-01-04 | Boston Biomedical, Inc. | Methods for treating cancer |
CN107698593A (en) * | 2016-08-09 | 2018-02-16 | 南京天印健华医药科技有限公司 | Heterocyclic compound as FGFR inhibitor |
CN106432228A (en) * | 2016-09-06 | 2017-02-22 | 浙江司太立制药股份有限公司 | 4-oximido-1-piperidyl fragment containing 7-azaindolin-2-one compound and preparation method therefor |
CN106397436A (en) * | 2016-09-06 | 2017-02-15 | 浙江司太立制药股份有限公司 | 5-bromo-7-azaindoline-2-one compounds and preparation method thereof |
WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
WO2019002889A1 (en) * | 2017-06-30 | 2019-01-03 | Industrial Technology Research Institute | Method for treating an autoimmune neurological disease and/or neurodegenerative disease and pharmaceutical formulations for a liquid dosage form and a controlled release dosage form |
CN110357878B (en) * | 2018-03-26 | 2022-04-12 | 武汉誉祥医药科技有限公司 | 1, 3-dihydro-2H-pyrrolo [3,2-b ] pyridin-2-one derivatives and medical use thereof |
EA202092490A1 (en) | 2018-04-18 | 2020-12-23 | Констеллейшен Фармасьютикалс, Инк. | METHYL-MODIFYING ENZYMES MODULATORS, COMPOSITIONS AND THEIR APPLICATION |
US11919912B2 (en) | 2018-05-21 | 2024-03-05 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
MX2021003156A (en) * | 2018-09-18 | 2021-05-14 | 1 Globe Biomedical Co Ltd | Treatment for non-alcoholic fatty liver disease. |
EP3852754A4 (en) * | 2018-09-18 | 2022-06-15 | 1Globe Biomedical Co., Ltd. | Treatment for obesity |
EP4157858A2 (en) * | 2020-05-29 | 2023-04-05 | The Regents of The University of Michigan | Small molecule inhibitors of grk5 and grk5 subfamily members and uses thereof |
CN111675647B (en) * | 2020-06-26 | 2022-03-01 | 深圳技术大学 | 2-indolone PAK1 inhibitor and application thereof in antitumor drugs |
WO2022011123A1 (en) * | 2020-07-10 | 2022-01-13 | Blossomhill Therapeutics, Inc. | Macrocycles and their use |
WO2023133375A1 (en) * | 2022-01-05 | 2023-07-13 | Blossomhill Therapeutics, Inc. | Macrocyclic compounds and use as kinase inhibitors |
CN114213396B (en) * | 2022-01-27 | 2023-03-24 | 深圳市乐土生物医药有限公司 | Indole-2-ketone compound and preparation method and application thereof |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE640616A (en) | 1962-12-19 | |||
US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
AU7284096A (en) * | 1995-10-09 | 1997-04-30 | Dieter Binder | Heterocyclically-substituted 1-indole carboxamides as cyclo-oxygenase-2 inhibitors |
GB9716557D0 (en) * | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
KR20010101266A (en) * | 1998-12-17 | 2001-11-14 | 프리돌린 클라우스너, 롤란드 비. 보레르 | 4-aryloxindoles as inhibitors of jnk protein kinases |
EP1244672B1 (en) * | 1999-12-21 | 2005-07-20 | Sugen, Inc. | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
SK287142B6 (en) * | 2000-02-15 | 2010-01-07 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors, pharmacutical composition and use |
CA2414468A1 (en) * | 2000-06-30 | 2002-01-10 | Sugen, Inc. | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
US6677368B2 (en) * | 2000-12-20 | 2004-01-13 | Sugen, Inc. | 4-aryl substituted indolinones |
AR038957A1 (en) * | 2001-08-15 | 2005-02-02 | Pharmacia Corp | COMBINATION THERAPY FOR CANCER TREATMENT |
RU2006117635A (en) * | 2003-10-24 | 2007-12-10 | Шеринг Акциенгезельшафт (De) | DERIVATIVES OF INDOLINON AND THEIR APPLICATION FOR TREATMENT OF PATHOLOGICAL CONDITIONS SUCH AS A MALIGNANT NEW FORMATION |
JP2008524165A (en) * | 2004-12-17 | 2008-07-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Indolinone and its use as an antiproliferative agent |
US20070032555A1 (en) | 2005-07-01 | 2007-02-08 | Concert Pharmaceuticals Inc. | Novel aryloxyphenyl-propanamines |
US20070116643A1 (en) | 2005-07-01 | 2007-05-24 | Concert Pharmaceuticals Inc. | Novel aryloxypropanamines |
AU2006275702A1 (en) | 2005-07-29 | 2007-02-08 | Concert Pharmaceuticals Inc. | Novel pharmaceutical compounds |
ES2396365T3 (en) | 2005-07-29 | 2013-02-21 | Concert Pharmaceuticals Inc. | New benzo [D] [1,3] -dioxol derivatives deuterated as serotonin reuptake inhibitors |
KR20080091369A (en) * | 2006-01-18 | 2008-10-10 | 암젠 인크 | Thiazole compounds as protein kinase b (pkb) inhibitors |
CN101007801A (en) * | 2006-01-27 | 2007-08-01 | 上海恒瑞医药有限公司 | Pyrrole substituted 2-dihydromolindone derivative, its preparation method and medical uses |
BRPI0717805A2 (en) * | 2006-10-06 | 2013-10-29 | Irm Llc | PROTEIN KINASE INHIBITORS AND METHODS OF USE |
EP3037419B1 (en) | 2007-09-06 | 2019-09-04 | Boston Biomedical, Inc. | Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases |
US8507488B2 (en) * | 2008-05-13 | 2013-08-13 | Irm Llc | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors |
TW201011002A (en) * | 2008-07-29 | 2010-03-16 | Boehringer Ingelheim Int | New compounds |
US9187454B2 (en) * | 2013-03-13 | 2015-11-17 | Boston Biomedical, Inc. | Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof |
US9227962B2 (en) * | 2013-03-13 | 2016-01-05 | Boston Biomedical, Inc. | Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative |
CN106132412A (en) * | 2014-01-27 | 2016-11-16 | 北京强新生物科技有限公司 | The new method for the treatment of cancer |
-
2014
- 2014-03-13 CA CA2904152A patent/CA2904152A1/en not_active Abandoned
- 2014-03-13 SG SG10201806965XA patent/SG10201806965XA/en unknown
- 2014-03-13 AU AU2014243869A patent/AU2014243869A1/en not_active Abandoned
- 2014-03-13 CN CN201480026333.XA patent/CN105408320B/en active Active
- 2014-03-13 RU RU2019104092A patent/RU2019104092A/en unknown
- 2014-03-13 BR BR112015022431A patent/BR112015022431A2/en not_active Application Discontinuation
- 2014-03-13 EP EP14721620.4A patent/EP2970206A1/en not_active Withdrawn
- 2014-03-13 US US14/774,803 patent/US20160031888A1/en not_active Abandoned
- 2014-03-13 SG SG11201507346PA patent/SG11201507346PA/en unknown
- 2014-03-13 JP JP2016502156A patent/JP6378308B2/en not_active Expired - Fee Related
- 2014-03-13 RU RU2015143526A patent/RU2015143526A/en not_active Application Discontinuation
- 2014-03-13 WO PCT/US2014/026498 patent/WO2014160401A1/en active Application Filing
- 2014-03-13 KR KR1020157028817A patent/KR20150127249A/en not_active Application Discontinuation
- 2014-03-13 MX MX2015011456A patent/MX2015011456A/en unknown
-
2015
- 2015-08-31 IL IL240960A patent/IL240960A0/en unknown
-
2016
- 2016-07-12 HK HK16108180.5A patent/HK1220184A1/en unknown
-
2018
- 2018-07-06 JP JP2018129002A patent/JP2018168187A/en active Pending
- 2018-09-21 AU AU2018233033A patent/AU2018233033A1/en not_active Abandoned
- 2018-11-30 US US16/206,010 patent/US20190241569A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX2015011456A (en) | 2016-05-31 |
AU2014243869A1 (en) | 2015-09-24 |
CN105408320B (en) | 2019-08-13 |
RU2015143526A (en) | 2017-04-19 |
JP2016513656A (en) | 2016-05-16 |
KR20150127249A (en) | 2015-11-16 |
US20160031888A1 (en) | 2016-02-04 |
IL240960A0 (en) | 2015-11-30 |
RU2019104092A (en) | 2019-03-20 |
AU2018233033A1 (en) | 2018-10-11 |
JP2018168187A (en) | 2018-11-01 |
US20190241569A1 (en) | 2019-08-08 |
CN105408320A (en) | 2016-03-16 |
JP6378308B2 (en) | 2018-08-22 |
SG11201507346PA (en) | 2015-10-29 |
WO2014160401A1 (en) | 2014-10-02 |
CA2904152A1 (en) | 2014-10-02 |
BR112015022431A2 (en) | 2017-05-09 |
EP2970206A1 (en) | 2016-01-20 |
HK1220184A1 (en) | 2017-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201806965XA (en) | 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer | |
PH12017502090A1 (en) | Heterocyclic amides as kinase inhibitors | |
CY1120635T1 (en) | AMINOETERALYL BENZAMIDS AS KINASE INhibitors | |
MX2020011558A (en) | Imidazolonyl quinolines and use thereof as atm kinase inhibitors. | |
TR201911151T4 (en) | Jak2 and alk2 inhibitors and their usage methods. | |
NZ711376A (en) | Heteroaryl compounds and uses thereof | |
MY173126A (en) | Arylquinazolines | |
EA201590920A1 (en) | Heteroaryl-Substituted Pyridyl Compounds Applied as Kinase Modulators | |
MX344335B (en) | Benzonitrile derivatives as kinase inhibitors. | |
EA201591913A1 (en) | PROTEINKINASE INHIBITORS | |
MX2015012431A (en) | Pyrrole amide inhibitors. | |
MX2015011514A (en) | Heteroaryl compounds and uses thereof. | |
MX2016001011A (en) | Substituted quinazolin-4-one derivatives. | |
MX2012013197A (en) | Indazole inhibitors of kinase. | |
MX341456B (en) | Amino-quinolines as kinase inhibitors. | |
MX2013001361A (en) | 4-(1h-indol-3-yl) -pyrimidines as alk inhibitors. | |
PH12015502611A1 (en) | Heterocyclic compounds as hedgehog signaling pathway inhibitors | |
MX2013012977A (en) | Thiazole derivatives. | |
MX2018008362A (en) | Quinolin-2-one derivatives. | |
PH12016500347A1 (en) | Triazolopyridine compounds, compositions and methods of use thereof | |
MX2016007810A (en) | N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase. | |
MX2015011660A (en) | 6-[4-(1 h-imidazol-2-yl)piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity. | |
MX2015012386A (en) | Cdk9 kinase inhibitors. | |
AR092772A1 (en) | DERIVATIVE OF 7-AZAINDOL | |
MD4215C1 (en) | Inhibitor of human myeloid leukemia based on N-(4-(5-(pyridin-2-yl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)-2-(pyridin-2-ylmethylen)-hydrazinecarbothioamide |